

# REVENIO GROUP

2/9/2026 10:40 am EET

This is a translated version of "Arvostus historiallisen alhaisella tasolla" report, published on 2/8/2026



Juha Kinnunen  
+358 40 778 1368  
juha.kinnunen@inderes.fi

INDERES CORPORATE CUSTOMER  
**COMPANY REPORT**



# Valuation reaches historic lows

We raise our recommendation for Revenio to **Buy** (was **Accumulate**), but we revise our target price to EUR 26.0 (from EUR 28.0). The share price has continued its steep decline despite EBIT growth, and at the same time, the share's valuation has fallen to a practically historically low level (forward-looking EV/EBIT 15x). There are concerns surrounding the industry, especially after Zeiss's unpleasant profit warning, but we consider these concerns exaggerated for Revenio and estimate that the company's earnings are firmly on an upward trend this year. Revenio will publish its Q4 report on Wednesday at around 9:00 am EET.

## We expect a good result from a seasonally strong Q4

We estimate Revenio's Q4 revenue to have been 31.8 MEUR (+4% reported, +7% FX-adjusted). For the full year 2025, this would imply 8.6% currency-adjusted growth, while the company's guidance is 6-15%. We estimate that growth has been supported by deliveries of the renewed iCare MAIA microperimeter and iCare ST500 sales, in addition to the traditional core business. We estimate that the recurring business from software licenses, maintenance agreements, and probe sales accounts for roughly one-third of Revenio's revenue. We expect adjusted EBIT to have been 9.1 MEUR, which would imply a "normal" margin of 28.6% for the company for the period. We estimate gross margin remained at 70%, but earnings are weighed down by investments in US sales, clinical trials, and the FDA process for the iCare ILLUME solution. For the full year 2025, we expect EBIT to have increased by 11%, even though EPS, pressured by exchange rates, remains at the previous year's level. We expect the Board of Directors to propose a dividend of EUR 0.42 (2024: EUR 0.40), which would continue the long upward trend of the dividend. The company's balance sheet is strong and net debt-free.

## We expect growth to accelerate, but there are also risks

We forecast Revenio's revenue growth to accelerate to double

digits (11%) in 2026, which should be reflected in the company's guidance. Although the euro remains strong against the US dollar, at the current exchange rate of 1.18, this would no longer cause a significant headwind to reported growth after Q1. In addition to the traditional core business, growth is driven by iCare ILLUME screening solutions (incl. RetCAD), for example, which are again a step larger than last year. We expect the 2026 EBIT margin to be 26.6% (2025e: 25.2%). Overall, Revenio's guidance could be, for example, "currency-adjusted revenue growth of 7-15% and profitability at a good level excluding one-off items."

We made small negative revisions to our earnings estimates, and our 2026 earnings estimates decreased by less than 5%. Although we believe the outlook is still good, new dark clouds have appeared on the horizon. Carl Zeiss Medtech, one of the largest companies in the sector, recently issued a severe profit warning regarding its year-end results and simultaneously withdrew its full-year guidance. Although the company's problems were, in our view, concentrated in China (a small market for Revenio) and in a business segment in which Revenio is not involved, the company also lamented a weakened appetite for investment in the United States. The United States is Revenio's main market, so this represents a clear risk.

## The valuation has sunk to a historical low for the iCare era

Revenio's EV/EBIT is only 15x based on current year estimates, whereas during the iCare era, the corresponding multiple has mostly ranged between 20-30x. Although the company's earnings growth has slowed and there is more uncertainty in the market than usual, we believe this is a clear overreaction. Of course, there is a risk that the market has broadly deteriorated and Revenio, along with Zeiss, would be on the list of those suffering. However, we do not see any material changes in the longer-term drivers and consider Revenio's position in the industry to be very strong, which makes the prevailing uncertainty an attractive buying opportunity.

## Recommendation

**Buy**  
(was Accumulate)

## Business risk



**Target price:**  
**EUR 26.00**  
(was EUR 28.00)

**Share price:**  
EUR 19.28

## Valuation risk



	2024	2025e	2026e	2027e
<b>Revenue</b>	104	110	122	139
<b>growth-%</b>	7%	6%	11%	13%
<b>EBIT adj.</b>	26.0	28.5	32.6	39.2
<b>EBIT-% adj.</b>	25.1 %	25.8 %	26.6 %	28.3 %
<b>Net income</b>	18.5	18.8	25.2	31.1
<b>EPS (adj.)</b>	0.73	0.73	0.95	1.16

<b>P/E (adj.)</b>	36.5	26.5	20.4	16.6
<b>P/B</b>	6.6	4.4	4.0	3.5
<b>Dividend yield-%</b>	1.5 %	2.2 %	2.6 %	3.3 %
<b>EV/EBIT (adj.)</b>	27.1	17.4	14.8	11.8
<b>EV/EBITDA</b>	23.2	15.4	12.8	10.4
<b>EV/S</b>	6.8	4.5	3.9	3.3


Source: Inderes

## Guidance


(Unchanged)

Revenio Group's exchange rate-adjusted net sales are estimated to grow 5-10% from the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level.


## Share price



## Revenue and EBIT-% (adj.)



## EPS and dividend



## Value drivers

- Earnings growth in the short and long term
- More than 30% of revenue is recurring and this share is growing
- Strong competitive protection and market growth drivers offering support
- New products, software and AI have significant long-term potential
- Excellent track record of value creation
- Potential acquisitions (especially OCT)

## Risk factors

- The patent protection of the iCare tonometer has been reduced and competition has emerged in RBT technology, which is a long-term threat
- Success in sometimes unpredictable FDA approval processes (especially ILLUME incl. Thirona)
- Medium-term commercial breakthrough success of growth products (ILLUME, HOME family and Thirona cluster)
- Success in the rapid growth of imaging devices
- Increasing competition and the AI transition

	2025e	2026e	2027e
<b>Share price</b>	19.3	19.3	19.3
<b>Number of shares, millions</b>	26.7	26.7	26.7
<b>Market cap</b>	514	514	514
<b>EV</b>	497	481	462
<b>P/E (adj.)</b>	26.5	20.4	16.6
<b>P/E</b>	27.4	20.4	16.6
<b>P/B</b>	4.4	4.0	3.5
<b>P/S</b>	4.7	4.2	3.7
<b>EV/Sales</b>	4.5	3.9	3.3
<b>EV/EBITDA</b>	15.4	12.8	10.4
<b>EV/EBIT (adj.)</b>	17.4	14.8	11.8
<b>Payout ratio (%)</b>	59.7 %	52.8 %	55.0 %
<b>Dividend yield-%</b>	2.2 %	2.6 %	3.3 %

Source: Inderes

# Q4'25 preview: We expect a good result from a seasonally strong period

Revenio will publish its 2025 financial statement release on Wednesday, February 11, 2026. The conference call related to the earnings release can be followed later here at 3:30 pm EET. We expect a good performance from Revenio in a seasonally strong quarter, but the comparison period is also strong. We expect that deliveries of the new iCare MAIA microperimeter and sales of the iCare ST500 tonometer will support growth, while recurring probe sales provide a stable foundation. Our eyes are on the 2026 guidance and updates on the progress of the iCare ILLUME screening solution's FDA approval process.

## Strong foundation and support from new products

We estimate Revenio's Q4 revenue to have been 31.8 MEUR, which would represent reported growth of around 4% compared to the prior year. We expect the FX-adjusted growth to have been around 7%, as the development of the US dollar continues to create a headwind for reported growth. The company has guided for full-year revenue

growth at constant exchange rates of 6-15%, and with our Q4 estimate, full-year growth at constant exchange rates would be 8.6%.

The key growth drivers are deliveries of the iCare MAIA microperimeter, which received FDA approval in March 2025, and the sales progress of the iCare ST500 tonometer, launched in fall 2024. We also expect sales of the iCare ILLUME screening solution and the related iCare DRSplus camera to have remained strong in Europe. The US market, which accounts for about half of the company's revenue, has remained strong despite significant uncertainties, in our assessment.

## High gross margin supports earnings despite cost pressures

We expect Revenio's Q4 EBIT to have been 9.1 MEUR, corresponding to an EBIT margin of 28.6%. This would mean flat EBIT development year-on-year and a slightly

weakening EBIT margin. Profitability is supported by the company's typically very high gross margin, which we estimate remained at around 70%. However, results are burdened by increased personnel costs, particularly due to the strengthening of the US sales organization, and investments in clinical trials. Costs related to the iCare ILLUME solution's FDA approval process are also likely to weigh on profitability, although we expect these to have been relatively small so far.

## Dividend remains on a growth path

We expect the company's Board of Directors to propose a dividend of EUR 0.42 per share (2024: EUR 0.40), which would continue its very long series of growing dividends. Over the past five years, the company has increased its dividend by EUR 0.02 annually, and we expect this trend to continue. The company would have ample reserves for this, as its balance sheet is strong and it is net debt-free.

Estimates MEUR / EUR	Q4'24	Q4'25	Q4'25e Inderes	Q4'25e Consensus	Consensus		2025e Inderes
	Comparison	Actualized			Low	High	
<b>Revenue</b>	30.5		31.8	32.7	31.6	- 34.4	110
<b>EBIT</b>	9.1		9.1	9.4	8.9	- 9.9	27.8
<b>EPS (reported)</b>	0.25		0.26	0.27	0.25	- 0.29	0.70
<b>DPS</b>	0.40		0.42	0.42	0.40	- 0.44	0.42
<b>Revenue growth-%</b>	4.8 %		4.0 %	7.1 %	3.5 %	- 12.6 %	6.5 %
<b>EBIT-%</b>	29.9 %		28.6 %	28.7 %	28.2 %	- 28.8 %	25.2 %

Source: Inderes & Modular  
Finance 2/3/2026 (consensus)

# We expect growth to accelerate, but there are risks

## The guidance should indicate accelerating growth

The most important aspect of the Q4 report is the company's guidance for 2026. We forecast revenue of around 122 MEUR for 2026, which would imply an acceleration of growth to double digits (11%). Although the euro remains strong against the US dollar, at the current exchange rate of 1.18, this would no longer cause a significant headwind to reported growth after Q1. The market still seemed relatively lively, at least towards the end of the year, which could accelerate the growth of the old "core business." However, the highest expectations come from growth segments, such as screening solutions, which are now somewhat larger and thus more visible in the Group figures.

Revenio's guidance on profitability has traditionally been "at a good level excluding non-recurring items," which is likely to be the wording this time as well. In connection with the update, we slightly cut our profitability forecasts as we still see cost pressures at Revenio. Revenio's costs have grown faster than we anticipated in 2025, and there

will be an additional 2 MEUR in FDA study-related costs in 2026. The changes were small, and our 2026 earnings estimates decreased by less than 5%. We now expect the 2026 EBIT margin to be 26.6%, which is sturdily at a "good level."

A key item to monitor is the timeline for FDA approval of the iCare ILLUME screening solution and the Thirona AI algorithm. The timeline has been extended, and in the summer of 2025, the company estimated that FDA approval would inevitably be delayed until 2027. We are now seeking an update on this, as AI should also be deployed in the large and more advanced US screening market compared to Europe.

## Zeiss' challenges are also a risk for Revenio

Carl Zeiss Meditec, a significant player in the field, issued a severe profit warning at the end of January, which has negatively impacted the entire industry. Zeiss' Q1 (October–December) revenue (467 MEUR vs. 490 MEUR) and especially profitability (EBITA 8 MEUR vs. 35 MEUR) fell

sharply below the comparison period, and the company simultaneously withdrew its guidance for the entire financial year. Most of Zeiss's challenges were, in our view, related to China (significant for Zeiss but minor for Revenio) and the intraocular lens (IOL) business, which Revenio does not have at all. However, the company also mentioned a decrease in investment willingness in the United States, which is a direct risk factor for Revenio as well. Revenio's comments on the development of market demand in the United States are once again one of the biggest points of interest.

While we consider Zeiss's significant difficulties a potential risk for Revenio, we would not draw direct conclusions from this. The companies' product portfolios differ significantly, and their demand has varied considerably in recent years. When Revenio had a "weak season" in the US and the company had to issue a profit warning in August 2023, Zeiss reported good figures due to its strong order book. Since then, the situation has clearly turned in Revenio's favor, and Zeiss's problems have deepened.

Estimate revisions	2025e	2025e	Change	2026e	2026e	Change	2027e	2027e	Change
MEUR / EUR	Old	New	%	Old	New	%	Old	New	%
<b>Revenue</b>	110	110	0%	122	122	0%	139	139	0%
<b>EBITDA</b>	32.3	32.3	0%	38.8	37.5	-3%	44.6	44.3	-1%
<b>EBIT (exc. NRIs)</b>	28.5	28.5	0%	33.8	32.6	-4%	39.5	39.2	-1%
<b>EBIT</b>	27.8	27.8	0%	33.8	32.6	-4%	39.5	39.2	-1%
<b>PTP</b>	25.0	25.0	0%	34.1	32.8	-4%	40.2	39.8	-1%
<b>EPS (excl. NRIs)</b>	0.73	0.73	0%	0.98	0.95	-4%	1.16	1.16	0%
<b>DPS</b>	0.42	0.42	0%	0.50	0.50	0%	0.64	0.64	0%

Source: Inderes

# Historically low valuation

## Valuation multiples have fallen historically low

Revenio's valuation is already attractive based on 2025 estimates (EV/EBIT 17x) and downright inexpensive with the earnings growth of the current year (2026e EV/EBIT 15x). According to our calculations, the valuation has not been this low in the last 10 years, or effectively throughout the entire iCare era, as the forward-looking EV/EBIT multiple has mostly ranged between 20-30x during this period. Although Revenio's development and earnings growth rate have slowed in recent years amid a challenging market environment following a wave of investments, we still consider the valuation level exceptionally low and see clear upside potential as the situation eventually normalizes. In our view, Revenio's industry position and competitiveness have not weakened, as evidenced by the company's exceptionally high margins.

The 2026 earnings forecast is based on clear revenue growth (2026e +11%), which naturally involves risks, especially before the financial statement report and guidance. We consider Revenio's strong performance to be the most likely scenario for the coming years due to the company's many positive drivers, but this naturally requires some support from the market. Once the company proves it can maintain the earnings growth trajectory we expect, we estimate that the acceptable valuation will also gradually increase.

Revenio is well positioned in an industry with strong structural long-term growth drivers and deep moats (patents, brand, slow-moving nature, and high barrier to entry). In the coming years, we believe the earnings growth prospects are good as new products slowly start to drive growth. In addition, Revenio will continue to expand its

product portfolio through both in-house product development and acquisitions, which we believe are well positioned to create shareholder value.

## Relative valuation is quite neutral

Revenio has historically traded at a premium to the peer group we use, which we believe is justified as long as the size of the premium remains reasonable. The company is growing faster than the industry and its long-term prospects are strong, while many of its future earnings drivers are still maturing. Compared to its competitors, Revenio's performance has also been good recently.

The median 2026e EV/EBIT for the peer group is now around 17x, which is slightly higher than Revenio (15x). Zeiss, previously among the best in the group, has faced difficulties in recent years, causing its stock to plummet and its valuation to be low. However, after the recent profit warning, it is difficult to say what level the 2026 consensus estimate will ultimately reach. With Topcon delisted, there are even fewer relevant peers. We consider Revenio's relative valuation to be moderate at the moment, but changes in peer valuations do not drive our view on the stock.


## DCF could support an even higher target price

Our DCF calculation indicates a value of roughly EUR 28 for Revenio's share, even though we have lowered our long-term margin assumptions and our required rate of return is a reasonably high 8.4% given the company's risk profile. The company's business generates strong free cash flow because it does not tie up significant capital, and the majority of R&D costs are expensed directly.

Valuation	2025e	2026e	2027e
Share price	19.3	19.3	19.3
Number of shares, millions	26.7	26.7	26.7
Market cap	514	514	514
EV	497	481	462
P/E (adj.)	26.5	20.4	16.6
P/E	27.4	20.4	16.6
P/B	4.4	4.0	3.5
P/S	4.7	4.2	3.7
EV/Sales	4.5	3.9	3.3
EV/EBITDA	15.4	12.8	10.4
EV/EBIT (adj.)	17.4	14.8	11.8
Payout ratio (%)	59.7 %	52.8 %	55.0 %
Dividend yield-%	2.2 %	2.6 %	3.3 %

Source: Inderes




## Verrokkiryhmän arvostuskertoimet (2026e)



# Valuation table

Valuation	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e
<b>Share price</b>	50.3	55.6	38.6	25.2	26.6	<b>19.3</b>	<b>19.3</b>	<b>19.3</b>	<b>19.3</b>
<b>Number of shares, millions</b>	26.6	26.7	26.6	26.6	26.7	<b>26.7</b>	<b>26.7</b>	<b>26.7</b>	<b>26.7</b>
<b>Market cap</b>	1337	1482	1026	670	709	<b>514</b>	<b>514</b>	<b>514</b>	<b>514</b>
<b>EV</b>	1335	1482	1015	667	702	<b>497</b>	<b>481</b>	<b>462</b>	<b>442</b>
<b>P/E (adj.)</b>	87.3	79.6	47.1	33.4	36.5	<b>26.5</b>	<b>20.4</b>	<b>16.6</b>	<b>14.6</b>
<b>P/E</b>	>100	85.7	47.1	35.1	38.2	<b>27.4</b>	<b>20.4</b>	<b>16.6</b>	<b>14.6</b>
<b>P/B</b>	19.2	18.9	11.3	6.7	6.6	<b>4.4</b>	<b>4.0</b>	<b>3.5</b>	<b>3.1</b>
<b>P/S</b>	21.9	18.8	10.6	6.9	6.9	<b>4.7</b>	<b>4.2</b>	<b>3.7</b>	<b>3.3</b>
<b>EV/Sales</b>	21.9	18.8	10.5	6.9	6.8	<b>4.5</b>	<b>3.9</b>	<b>3.3</b>	<b>2.9</b>
<b>EV/EBITDA</b>	61.5	57.6	30.6	22.0	23.2	<b>15.4</b>	<b>12.8</b>	<b>10.4</b>	<b>9.1</b>
<b>EV/EBIT (adj.)</b>	70.0	63.3	34.2	24.4	27.1	<b>17.4</b>	<b>14.8</b>	<b>11.8</b>	<b>10.1</b>
<b>Payout ratio (%)</b>	63.6 %	52.4 %	43.9 %	52.9 %	57.5 %	<b>59.7 %</b>	<b>52.8 %</b>	<b>55.0 %</b>	<b>60.0 %</b>
<b>Dividend yield-%</b>	0.6 %	0.6 %	0.9 %	1.5 %	1.5 %	<b>2.2 %</b>	<b>2.6 %</b>	<b>3.3 %</b>	<b>4.1 %</b>

Source: Inderes



# Peer group valuation

Peer group valuation Company	Market cap MEUR	EV MEUR	EV/EBIT		EV/EBITDA		EV/S		P/E		Dividend yield-%	
			2025e	2026e	2025e	2026e	2025e	2026e	2025e	2026e	2025e	2026e
Revenio Group	507	505	17.2	14.9	14.8	12.9	4.5	4.1	23.9	19.6	2.3	2.6
Cooper Companies	13312	15343	17.3	15.8	14.5	13.3	4.4	4.2	19.5	17.7		
Ametek	44858	46406	28.3	25.9	23.5	21.5	7.5	6.9	31.2	28.6	0.5	0.6
Medtronic	111922	129742	17.7	16.9	15.8	15.0	4.6	4.2	18.9	18.2	2.7	2.8
EssilorLuxottica	119807	131053	30.2	27.0	19.2	17.3	4.7	4.3	37.8	33.8	1.5	1.7
Carl Zeiss Meditec	2426	2921	12.4	12.5	8.0	7.8	1.3	1.3	16.1	16.1	2.4	2.4
Demand	5507	8131	15.4	13.6	11.2	10.0	2.7	2.4	16.7	14.3		
Optomed (Inderes)	83	79				2004.7	4.6	4.2				
<b>Revenio Group (Inderes)</b>	<b>514</b>	<b>497</b>	<b>17.4</b>	<b>14.8</b>	<b>15.4</b>	<b>12.8</b>	<b>4.5</b>	<b>3.9</b>	<b>26.5</b>	<b>20.4</b>	<b>2.2</b>	<b>2.6</b>
<b>Average</b>			<b>21.8</b>	<b>19.8</b>	<b>17.0</b>	<b>214.3</b>	<b>4.4</b>	<b>4.0</b>	<b>26.4</b>	<b>23.9</b>	<b>1.5</b>	<b>1.6</b>
<b>Median</b>			<b>17.7</b>	<b>16.9</b>	<b>15.8</b>	<b>16.1</b>	<b>4.5</b>	<b>4.2</b>	<b>23.9</b>	<b>19.6</b>	<b>1.5</b>	<b>1.7</b>
<b>Diff-% to median</b>			<b>-1%</b>	<b>-13%</b>	<b>-2%</b>	<b>-21%</b>	<b>-1%</b>	<b>-6%</b>	<b>11%</b>	<b>4%</b>	<b>46%</b>	<b>57%</b>

Source: Refinitiv / Inderes

# Income statement

Income statement	2022	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25	Q3'25	Q4'25e	2025e	2026e	2027e	2028e
<b>Revenue</b>	<b>97.0</b>	<b>96.6</b>	<b>23.6</b>	<b>25.4</b>	<b>23.9</b>	<b>30.5</b>	<b>104</b>	<b>26.1</b>	<b>26.5</b>	<b>25.9</b>	<b>31.8</b>	<b>110</b>	<b>122</b>	<b>139</b>	<b>154</b>
Tonometers (estimate)	58.5	57.4	14.9	16.0	13.2	17.1	61.3	16.4	15.9	13.6	17.3	63.2	68.9	75.8	83.4
Imaging devices (estimate)	36.2	36.6	8.0	8.7	9.9	12.6	39.2	8.9	9.8	11.4	13.5	43.5	48.9	54.8	60.3
Software (estimate)	2.2	2.6	0.7	0.7	0.8	0.8	3.0	0.8	0.8	0.9	1.0	3.5	4.5	8.0	10.0
Other products (estimate)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>EBITDA</b>	<b>33.1</b>	<b>30.3</b>	<b>6.2</b>	<b>7.1</b>	<b>6.7</b>	<b>10.3</b>	<b>30.2</b>	<b>7.7</b>	<b>7.2</b>	<b>7.2</b>	<b>10.1</b>	<b>32.3</b>	<b>37.5</b>	<b>44.3</b>	<b>48.7</b>
Depreciation	-3.4	-3.9	-1.1	-1.8	-1.2	-1.1	-5.2	-1.1	-1.1	-1.1	-1.1	-4.4	-5.0	-5.1	-4.7
<b>EBIT (excl. NRI)</b>	<b>29.7</b>	<b>27.3</b>	<b>5.1</b>	<b>6.0</b>	<b>5.6</b>	<b>9.2</b>	<b>26.0</b>	<b>6.6</b>	<b>6.6</b>	<b>6.2</b>	<b>9.1</b>	<b>28.5</b>	<b>32.6</b>	<b>39.2</b>	<b>44.0</b>
<b>EBIT</b>	<b>29.7</b>	<b>26.3</b>	<b>5.1</b>	<b>5.3</b>	<b>5.5</b>	<b>9.1</b>	<b>25.0</b>	<b>6.6</b>	<b>6.1</b>	<b>6.0</b>	<b>9.1</b>	<b>27.8</b>	<b>32.6</b>	<b>39.2</b>	<b>44.0</b>
Net financial items	-0.6	-1.0	-0.3	0.2	-0.4	0.1	-0.4	-1.1	-1.7	0.0	-0.1	-2.8	0.3	0.7	1.0
<b>PTP</b>	<b>29.1</b>	<b>25.4</b>	<b>4.8</b>	<b>5.5</b>	<b>5.1</b>	<b>9.2</b>	<b>24.6</b>	<b>5.6</b>	<b>4.4</b>	<b>6.0</b>	<b>9.0</b>	<b>25.0</b>	<b>32.8</b>	<b>39.8</b>	<b>45.0</b>
Taxes	-7.3	-6.3	-1.2	-1.3	-0.9	-2.7	-6.1	-1.4	-1.3	-1.4	-2.1	-6.2	-7.6	-8.8	-9.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Net earnings</b>	<b>21.8</b>	<b>19.1</b>	<b>3.6</b>	<b>4.1</b>	<b>4.3</b>	<b>6.5</b>	<b>18.5</b>	<b>4.2</b>	<b>3.1</b>	<b>4.6</b>	<b>6.9</b>	<b>18.8</b>	<b>25.2</b>	<b>31.1</b>	<b>35.1</b>
<b>EPS (adj.)</b>	<b>0.82</b>	<b>0.76</b>	<b>0.14</b>	<b>0.18</b>	<b>0.16</b>	<b>0.25</b>	<b>0.73</b>	<b>0.16</b>	<b>0.13</b>	<b>0.18</b>	<b>0.26</b>	<b>0.73</b>	<b>0.95</b>	<b>1.16</b>	<b>1.32</b>
<b>EPS (rep.)</b>	<b>0.82</b>	<b>0.72</b>	<b>0.14</b>	<b>0.16</b>	<b>0.16</b>	<b>0.25</b>	<b>0.70</b>	<b>0.16</b>	<b>0.12</b>	<b>0.17</b>	<b>0.26</b>	<b>0.70</b>	<b>0.95</b>	<b>1.16</b>	<b>1.32</b>
Key figures	2022	2023	Q1'24	Q2'24	Q3'24	Q4'24	2024	Q1'25	Q2'25	Q3'25	Q4'25e	2025e	2026e	2027e	2028e
<b>Revenue growth-%</b>	23.1 %	-0.4 %	1.8 %	14.2 %	8.9 %	4.8 %	7.2 %	10.5 %	4.2 %	8.1 %	4.0 %	6.5 %	11.0 %	13.3 %	10.9 %
<b>Adjusted EBIT growth-%</b>		-7.9 %	-16.6 %	9.0 %	-9.7 %	-2.5 %	-5.0 %	28.6 %	9.7 %	11.5 %	-1.7 %	9.7 %	14.3 %	20.3 %	12.3 %
<b>EBITDA-%</b>	34.1 %	31.4 %	26.3 %	27.8 %	27.9 %	33.6 %	29.2 %	29.6 %	27.3 %	27.7 %	31.9 %	29.3 %	30.7 %	32.0 %	31.7 %
<b>Adjusted EBIT-%</b>	30.6 %	28.3 %	21.8 %	23.5 %	23.3 %	30.3 %	25.1 %	25.4 %	24.7 %	24.0 %	28.6 %	25.8 %	26.6 %	28.3 %	28.6 %
<b>Net earnings-%</b>	22.5 %	19.8 %	15.3 %	16.3 %	17.8 %	21.4 %	17.9 %	16.0 %	11.6 %	17.8 %	21.8 %	17.0 %	20.6 %	22.4 %	22.8 %

Source: Inderes

# Balance sheet

Assets	2023	2024	2025e	2026e	2027e
<b>Non-current assets</b>	<b>77.5</b>	<b>83.7</b>	<b>84.0</b>	<b>83.2</b>	<b>82.0</b>
Goodwill	59.4	63.3	63.3	63.3	63.3
Intangible assets	7.1	11.4	11.4	10.2	8.6
Tangible assets	2.3	2.4	2.7	3.1	3.5
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	2.3	0.6	0.6	0.6	0.6
Other non-current assets	3.6	2.6	2.6	2.6	2.6
Deferred tax assets	2.8	3.4	3.4	3.4	3.4
<b>Current assets</b>	<b>48.3</b>	<b>47.0</b>	<b>54.1</b>	<b>71.9</b>	<b>94.2</b>
Inventories	10.5	10.1	9.9	9.8	11.1
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	16.3	16.2	16.5	18.3	20.8
Cash and equivalents	21.5	20.7	27.6	43.8	62.3
<b>Balance sheet total</b>	<b>137</b>	<b>141</b>	<b>148</b>	<b>164</b>	<b>184</b>


Source: Inderes

Liabilities & equity	2023	2024	2025e	2026e	2027e
<b>Equity</b>	<b>99.9</b>	<b>108</b>	<b>116</b>	<b>130</b>	<b>148</b>
Share capital	5.3	5.3	5.3	5.3	5.3
Retained earnings	43.5	52.2	60.3	74.3	92.1
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	51.1	50.2	50.2	50.2	50.2
Minorities	0.0	0.0	0.0	0.0	0.0
<b>Non-current liabilities</b>	<b>16.9</b>	<b>12.6</b>	<b>11.2</b>	<b>11.2</b>	<b>11.2</b>
Deferred tax liabilities	3.3	3.6	3.6	3.6	3.6
Provisions	0.6	0.6	0.6	0.6	0.6
Interest bearing debt	13.0	8.4	7.0	7.0	7.0
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.0	0.0	0.0
<b>Current liabilities</b>	<b>20.6</b>	<b>21.0</b>	<b>20.6</b>	<b>22.6</b>	<b>25.2</b>
Interest bearing debt	5.6	5.5	3.0	3.0	3.0
Payables	15.0	15.5	17.6	19.6	22.2
Other current liabilities	0.0	0.0	0.0	0.0	0.0
<b>Balance sheet total</b>	<b>137</b>	<b>141</b>	<b>148</b>	<b>164</b>	<b>184</b>

# DCF calculation

DCF model	2024	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	TERM
Revenue growth-%	7.2 %	6.5 %	11.0 %	13.3 %	10.9 %	12.0 %	10.0 %	8.0 %	5.0 %	5.0 %	3.2 %	3.2 %
EBIT-%	24.2 %	25.2 %	26.6 %	28.3 %	28.6 %	29.3 %	29.0 %	29.0 %	29.0 %	28.0 %	28.0 %	28.0 %
<b>EBIT (operating profit)</b>	<b>25.0</b>	<b>27.8</b>	<b>32.6</b>	<b>39.2</b>	<b>44.0</b>	<b>50.4</b>	<b>54.9</b>	<b>59.3</b>	<b>62.3</b>	<b>63.1</b>	<b>65.1</b>	
+ Depreciation	5.2	4.4	5.0	5.1	4.7	4.1	4.2	4.5	4.7	4.7	4.9	
- Paid taxes	-6.4	-6.2	-7.6	-8.8	-9.9	-11.4	-12.5	-13.5	-14.1	-14.4	-14.8	
- Tax, financial expenses	-0.2	-0.8	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	
+ Tax, financial income	0.1	0.1	0.2	0.2	0.3	0.4	0.5	0.5	0.5	0.6	0.6	
- Change in working capital	1.0	2.0	0.3	-1.1	-1.1	-1.3	-1.2	-1.1	-0.7	-0.8	-0.5	
<b>Operating cash flow</b>	<b>24.7</b>	<b>27.3</b>	<b>30.3</b>	<b>34.5</b>	<b>38.0</b>	<b>42.1</b>	<b>45.8</b>	<b>49.7</b>	<b>52.5</b>	<b>53.2</b>	<b>55.2</b>	
+ Change in other long-term liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-9.8	-3.7	-3.1	-3.1	-1.9	-3.9	-4.6	-4.7	-4.4	-4.9	-4.9	
<b>Free operating cash flow</b>	<b>14.9</b>	<b>23.6</b>	<b>27.2</b>	<b>31.4</b>	<b>36.1</b>	<b>38.2</b>	<b>41.2</b>	<b>45.0</b>	<b>48.2</b>	<b>48.3</b>	<b>50.3</b>	
+/- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	14.9	23.6	27.2	31.4	36.1	38.2	41.2	45.0	48.2	48.3	50.3	991
<b>Discounted FCFF</b>	<b>23.8</b>	<b>25.3</b>	<b>27.0</b>	<b>28.6</b>	<b>27.9</b>	<b>27.7</b>	<b>27.9</b>	<b>27.6</b>	<b>25.5</b>	<b>24.5</b>	<b>482</b>	
Sum of FCFF present value	748	724	699	672	643	615	588	560	532	507	482	
<b>Enterprise value DCF</b>	<b>748</b>											
- Interest bearing debt	-13.9											
+ Cash and cash equivalents	20.7											
-Minurities	0.0											
-Dividend/capital return	-10.7											
<b>Equity value DCF</b>	<b>744</b>											
<b>Equity value DCF per share</b>	<b>27.9</b>											

## Cash flow distribution







## WACC

Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E))	0.0 %
Cost of debt	4.0 %
Equity Beta	1.25
Market risk premium	4.75%
Liquidity premium	0.00%
Risk free interest rate	2.5 %
<b>Cost of equity</b>	<b>8.4 %</b>
<b>Weighted average cost of capital (WACC)</b>	<b>8.4 %</b>

Source: Inderes

■ 2025e-2029e ■ 2030e-2034e ■ TERM

# DCF sensitivity calculations and key assumptions in graphs



# Summary

Income statement	2022	2023	2024	2025e	2026e	Per share data	2022	2023	2024	2025e	2026e
<b>Revenue</b>	97.0	96.6	103.5	<b>110.2</b>	<b>122.3</b>	<b>EPS (reported)</b>	0.82	0.72	0.70	<b>0.70</b>	<b>0.95</b>
<b>EBITDA</b>	33.1	30.3	30.2	<b>32.3</b>	<b>37.5</b>	<b>EPS (adj.)</b>	0.82	0.76	0.73	<b>0.73</b>	<b>0.95</b>
<b>EBIT</b>	29.7	26.3	25.0	<b>27.8</b>	<b>32.6</b>	<b>OCF / share</b>	0.90	0.40	0.93	<b>1.02</b>	<b>1.13</b>
<b>PTP</b>	29.1	25.4	24.6	<b>25.0</b>	<b>32.8</b>	<b>OFCF / share</b>	0.79	0.09	0.56	<b>0.89</b>	<b>1.02</b>
<b>Net Income</b>	21.8	19.1	18.5	<b>18.8</b>	<b>25.2</b>	<b>Book value / share</b>	3.42	3.76	4.04	<b>4.34</b>	<b>4.87</b>
<b>Extraordinary items</b>	0.0	-1.0	-0.9	<b>-0.7</b>	<b>0.0</b>	<b>Dividend / share</b>	0.36	0.38	0.40	<b>0.42</b>	<b>0.50</b>
Balance sheet	2022	2023	2024	2025e	2026e	Growth and profitability	2022	2023	2024	2025e	2026e
<b>Balance sheet total</b>	136.1	137.4	141.3	<b>147.6</b>	<b>163.6</b>	<b>Revenue growth-%</b>	23%	0%	7%	<b>6%</b>	<b>11%</b>
<b>Equity capital</b>	90.9	99.9	107.7	<b>115.8</b>	<b>129.8</b>	<b>EBITDA growth-%</b>	29%	-9%	0%	<b>7%</b>	<b>16%</b>
<b>Goodwill</b>	59.8	59.4	63.3	<b>63.3</b>	<b>63.3</b>	<b>EBIT (adj.) growth-%</b>	27%	-8%	-5%	<b>10%</b>	<b>14%</b>
<b>Net debt</b>	-11.3	-2.9	-6.8	<b>-17.6</b>	<b>-33.8</b>	<b>EPS (adj.) growth-%</b>	17%	-8%	-3%	<b>0%</b>	<b>30%</b>
Cash flow	2022	2023	2024	2025e	2026e	<b>EBITDA-%</b>	34.1 %	31.4 %	29.2 %	<b>29.3 %</b>	<b>30.7 %</b>
<b>EBITDA</b>	33.1	30.3	30.2	<b>32.3</b>	<b>37.5</b>	<b>EBIT (adj.)-%</b>	30.6 %	28.3 %	25.1 %	<b>25.8 %</b>	<b>26.6 %</b>
<b>Change in working capital</b>	-1.5	-11.6	1.0	<b>2.0</b>	<b>0.3</b>	<b>EBIT-%</b>	30.6 %	27.3 %	24.2 %	<b>25.2 %</b>	<b>26.6 %</b>
<b>Operating cash flow</b>	24.0	10.5	24.7	<b>27.3</b>	<b>30.3</b>	<b>ROE-%</b>	25.7 %	20.0 %	17.9 %	<b>16.8 %</b>	<b>20.6 %</b>
<b>CAPEX</b>	-2.9	-8.2	-9.8	<b>-3.7</b>	<b>-3.1</b>	<b>ROI-%</b>	27.6 %	23.3 %	21.3 %	<b>22.9 %</b>	<b>25.1 %</b>
<b>Free cash flow</b>	21.1	2.4	14.9	<b>23.6</b>	<b>27.2</b>	<b>Equity ratio</b>	66.8 %	72.7 %	76.2 %	<b>78.4 %</b>	<b>79.4 %</b>
Valuation multiples	2022	2023	2024	2025e	2026e	<b>Gearing</b>	-12.5 %	-2.9 %	-6.3 %	<b>-15.2 %</b>	<b>-26.0 %</b>
<b>EV/S</b>	10.5	6.9	6.8	<b>4.5</b>	<b>3.9</b>						
<b>EV/EBITDA</b>	30.6	22.0	23.2	<b>15.4</b>	<b>12.8</b>						
<b>EV/EBIT (adj.)</b>	34.2	24.4	27.1	<b>17.4</b>	<b>14.8</b>						
<b>P/E (adj.)</b>	47.1	33.4	36.5	<b>26.5</b>	<b>20.4</b>						
<b>P/B</b>	11.3	6.7	6.6	<b>4.4</b>	<b>4.0</b>						
<b>Dividend-%</b>	0.9 %	1.5 %	1.5 %	<b>2.2 %</b>	<b>2.6 %</b>						

Source: Inderes

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years. Per-share figures are calculated using the number of shares at year-end.

# Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of the share is very attractive
Accumulate	The 12-month risk-adjusted expected shareholder return of the share is attractive
Reduce	The 12-month risk-adjusted expected shareholder return of the share is weak
Sell	The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at [www.inderes.fi/research-disclaimer](http://www.inderes.fi/research-disclaimer).

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

## Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
2/21/2020	Accumulate	31.00 €	28.85 €
3/19/2020	Buy	24.00 €	18.48 €
4/23/2020	Accumulate	25.00 €	22.75 €
8/7/2020	Reduce	34.00 €	33.50 €
10/23/2020	Reduce	36.00 €	38.05 €
12/21/2020	Reduce	44.00 €	48.65 €
2/12/2021	Accumulate	60.00 €	53.00 €
4/26/2021	Accumulate	65.00 €	59.20 €
	Analyst changed		
6/9/2021	Accumulate	65.00 €	59.50 €
8/6/2021	Reduce	65.00 €	64.80 €
10/22/2021	Accumulate	58.00 €	55.40 €
2/11/2022	Accumulate	48.00 €	44.30 €
4/7/2022	Reduce	48.00 €	47.96 €
4/29/2022	Reduce	48.00 €	47.58 €
8/5/2022	Reduce	52.00 €	54.30 €
10/28/2022	Reduce	40.00 €	39.48 €
1/27/2023	Reduce	40.00 €	37.62 €
2/10/2023	Reduce	38.00 €	37.26 €
1/27/2023	Reduce	40.00 €	37.62 €
2/10/2023	Reduce	38.00 €	37.26 €
3/20/2023	Accumulate	38.00 €	34.66 €
4/28/2023	Reduce	38.00 €	39.24 €
8/3/2023	Accumulate	26.00 €	24.08 €
8/11/2023	Accumulate	26.00 €	23.20 €
10/4/2023	Buy	26.00 €	19.81 €
10/27/2023	Buy	24.50 €	19.90 €
12/7/2023	Accumulate	25.50 €	23.66 €
2/16/2024	Reduce	28.00 €	27.94 €
4/4/2024	Accumulate	28.00 €	25.86 €
4/26/2024	Accumulate	28.00 €	23.86 €
8/9/2024	Accumulate	32.00 €	28.82 €
11/1/2024	Accumulate	32.00 €	29.50 €
1/20/2025	Accumulate	32.00 €	28.18 €
2/14/2025	Accumulate	30.00 €	27.60 €
4/30/2025	Accumulate	30.00 €	27.40 €
8/8/2025	Accumulate	28.00 €	24.60 €
10/31/2025	Accumulate	28.00 €	24.35 €
2/9/2026	Buy	26.00 €	19.28 €



# CONNECTING INVESTORS AND COMPANIES.

Inderes democratizes financial information by connecting investors and listed companies. For investors, we are an investing community and a trusted source of financial information and equity research. For listed companies, we are a partner in delivering high-quality investor relations. Over 500 listed companies in Europe use our investor relations products and equity research services to provide better investor communications to their shareholders.

Our goal is to be the most investor-minded company in finance. Inderes was founded in 2009 by investors, for investors. As a Nasdaq First North-listed company, we understand the day-to-day reality of our customers.

## Inderes Ab

Vattugatan 17, 5tr  
Stockholm  
+46 8 411 43 80

[inderes.se](http://inderes.se)

## Inderes Oyj

Porkkalankatu 5  
00180 Helsinki  
+358 10 219 4690

[inderes.fi](http://inderes.fi)

inder  
res.